Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Appointed director
Ovid Therapeutics Inc. (OVID) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/04/2023 8-K Quarterly results
Docs: "Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates"
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/05/2023 8-K Quarterly results
Docs: "Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates"
05/01/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors • Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases • Couples Ovid capabilities in rare CNS development with Graviton’s expertise in RhoA/ROCK2 signaling pathway to accelerate a series of clinical development programs • Development to focus on serious disorders that have few-to-no therapeutic options, including cerebral cavernous malformations and conditions presenting with seizures • Ovid to invest $10 million in preferred equity in Graviton and will fund development programs • Transaction has no milestone payments and Graviton is eligible for tiered double-digit royalties on commercial sal..."
04/27/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting • Interim 2-year findings show soticlestat appeared generally safe and well tolerated, consistent with prior studies • Sustained reduction in frequency of drop seizures among Lennox-Gastaut patients and convulsive seizures among Dravet patients were documented for up to two years • Sustained reductions were also seen in the frequency of all-seizures from baseline for up to 2 years across both cohorts • A separate post-hoc study of the Phase 2 ELEKTRA study presented at the meeting found a reduction in median seizure frequency across multiple seizure types measured NEW YORK, April 27, 2023 – Ovid Therapeutics Inc. re..."
03/13/2023 8-K Quarterly results
Docs: "Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results"
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
11/08/2022 8-K Quarterly results
Docs: "Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights"
08/09/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/15/2022 8-K Quarterly results
Docs: "Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results • Ovid executing on its strategy to build a leading epilepsy pipeline • OV329 expected to enter the clinic in 2022 • Organization reshaped to reduce personnel by 20% and increase operational efficiency • Targeted business development continues to support the pipeline NEW YORK, March 15, 2022 -- Ovid Therapeutics Inc. , a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021. "Ovid is disciplined in our focus to become a leader in epilepsy therapies. We are..."
01/03/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "License Agreement, by and between the Ovid Therapeutics Inc. and AstraZeneca AB",
"Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators"
11/10/2021 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Ovid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights and Financial Results"
10/07/2021 8-K Appointed a new director
08/18/2021 8-K Quarterly results
08/16/2021 8-K Quarterly results
Docs: "Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights"
08/11/2021 8-K/A Quarterly results
07/08/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/23/2021 8-K Quarterly results
06/11/2021 8-K Quarterly results
06/04/2021 8-K Quarterly results
05/18/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
04/19/2021 8-K Quarterly results
04/19/2021 8-K Quarterly results
04/09/2021 8-K Quarterly results
04/01/2021 8-K Quarterly results
03/30/2021 8-K Quarterly results
03/15/2021 8-K Quarterly results
03/03/2021 8-K Quarterly results
03/03/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy